Navigation Links
Study in mice discovers injection of heat-generating cells reduces belly fat
Date:9/5/2012

COLUMBUS, Ohio The injection of a tiny capsule containing heat-generating cells into the abdomens of mice led those animals to burn abdominal fat and initially lose about 20 percent of belly fat after 80 days of treatment.

Researchers conducting the study were surprised to see that the injected cells even acted like "missionaries," converting existing belly fat cells into so-called thermogenic cells, which use fat to generate heat.

Over time, the mice gained back some weight. But they resisted any dramatic weight gain on a high-fat diet and burned away more than a fifth of the cells that make up their visceral fat, which surrounds the organs and is linked to higher risk for Type 2 diabetes, cancer and heart disease.

The scientists took advantage of the heat-generating properties of a so-called good fat in the body, brown fat, to cut back on the white fat cells that compose the visceral fat that tends to accumulate in the belly.

(See related news release at http://researchnews.osu.edu/archive/visceralfat.htm.)

The scientists combined those brown fat thermogenic cells with genetically modified cells missing an enzyme that leads to visceral fat growth. The engineered cells were placed inside a gel-like capsule that allowed for release of its contents without triggering an immune response.

"With a very small number of cells, the effect of the injection of this capsule was more pronounced at the beginning, when the mice dramatically lost about 10 percent of their weight. They gained some weight back after that. But then we started to look at how much visceral fat was present, and we saw about a 20 percent reduction in those lipids. Importantly, other nontreated peripheral or subcutaneous fat, which has some beneficial health effects, remained the same. That's what we want," said Ouliana Ziouzenkova, assistant professor of human nutrition at Ohio State University and lead author of the study.

"We observed the mice for 80 days after injection and the capsule didn't break or cause any scarring or inflammation. This suggests it's a clean, safe potential therapy for obesity," added Ziouzenkova, also an investigator in Ohio State's Comprehensive Cancer Center and the Center for Clinical and Translational Science. Studies in larger animals would be needed before trials in humans could begin, she said.

If this were someday approved for humans, Ziouzenkova said such a therapy would be best suited to patients who develop visceral fat with aging, aren't able to exercise and shouldn't dramatically reduce their calories because that can cause the loss of beneficial subcutaneous fat. She also noted that anti-obesity drugs for humans currently on the market can reduce body weight by about 10 to 15 percent, but also have side effects.

The research is published in a recent issue of the journal Biomaterials.

A year ago, Ziouzenkova's lab identified an enzyme in mice that relates to fat accumulation after consumption of a high-fat diet, and she recently published a paper indicating that mice lacking that enzyme could stay lean even while eating excess fat. She applied those findings in this work by using the genetically modified cells that are missing that enzyme to potentially help boost the ability of brown fat cells to burn up visceral fat.

For this study, she collaborated with Ohio State chemists to create the capsules. They are composed of alginate-poly-L-lysine, a compound that creates enough of a barrier to encapsulate cells without signaling the immune system that it should react to a foreign object in the body, while also enabling nutrient supply to the encapsulated cells for their long-term survival.

The researchers used three groups of normal mice for the study, feeding them all a high-fat diet for 90 days. After that, five mice received no treatment, five were treated with empty capsules and five received an injection of active capsules containing genetically engineered cells. The capsules were injected into two areas of visceral fat in their abdomens.

The mice continued to eat a high-fat diet for another 80 days. The mice receiving no treatment continued to gain weight in those 80 days, while the mice receiving thermogenic cells lost weight for 23 days and then began to gain it back, eventually maintaining a steady weight even after continuing to eat excessive saturated fat. Mice receiving empty capsules also lost some weight, but the researchers determined in a separate pilot study that the sham injections did not reduce visceral fat.

The researchers examined visceral fat pads from the mice and determined that overall, lipid content was at least 20 percent lower in mice treated with active capsules compared to the placebo injection group of mice.

A closer look at exactly what was going on in the animals' cells showed that the injected cells produced high levels of a protein called Ucp1, which burns fat, suggesting that this protein assisted in the visceral fat reduction.

By tagging the injected cells with a fluorescent protein, the scientists could use imaging technology to track the cells in the body; this not only benefited the research, but also provides a way to safely remove these capsules if needed, Ziouzenkova noted.

"The injected cells were perfectly inversely correlated with lipids so the more injected cells we have capable of burning fat, the more fat gets burned," she said. "These injected cells worked almost like missionaries, starting to convert host cells and turning them into thermogenic cells."

Because that creation of heat could be uncomfortable inside a human body, the researchers analyzed the treated mice further to see if the thermogenesis in the belly would produce effects similar to hot flashes.

"Heat production was higher in injected animals, but it was not dramatically higher. So there is some kind of response, but it seems not to be at a magnitude impairing a patient's well-being," Ziouzenkova said. "The animals were also moving less than noninjected animals, but in spite of that, they were still able to lose visceral fat. Their glucose tolerance improved, as well, which is probably related to reduced visceral fat."

Ziouzenkova said she hopes to design additional capsules to target a variety of diseases beyond obesity.


'/>"/>
Contact: Ouliana Ziouzenkova
Ziouzenkova.1@osu.edu
614-292-5034
Ohio State University
Source:Eurekalert

Related biology news :

1. Study: How a high-fat diet and estrogen loss leads women to store more abdominal fat than men
2. Brainy beverage: Study reveals how green tea boosts brain cell production to aid memory
3. New study shows promise in using RNA nanotechnology to treat cancers and viral infections
4. Study identifies prime source of ocean methane
5. New Nature study illuminates 55 million years of the carbon cycle and climate history
6. GW professor receives grant to study the role of genes in drug addiction
7. Study shows hope of greater global food output, less environmental impact of agriculture
8. Controlling gait of horses may be possible, says key study from Texas A&M
9. New study evaluates noninvasive technology to determine heart disease
10. Zebrafish study explains why the circadian rhythm affects your health
11. University of Tennessee Team receives NSF support to study toxic water in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/1/2016)... Feb. 1, 2016  Today, the first day of ... plans to develop a first of its kind workplace ... IBM Watson. In the first application of ... IBM ), and Welltok will create a new ... with cognitive analytics, delivered on Welltok,s health optimization platform. ...
(Date:1/25/2016)... Software, the world-leading supplier of image data management solutions ... data management solution OMERO Plus for the newly established ... Photo - http://photos.prnewswire.com/prnh/20160125/325328LOGO ... analysis measures the characteristics and behavior of cells, tissues ... as health and disease, the presence or absence of ...
(Date:1/20/2016)... 20, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce the attainment ... are the result of the company,s laser focus on ... , it,s comprehensive, easy-to-use and highly affordable cloud-based ... Key MedNet growth achievements in 2015 include: ...
Breaking Biology News(10 mins):
(Date:2/5/2016)... , February 5, 2016 ... a biotechnology company focused on developing products for Regenerative ... requested Rare Pediatric Disease Designation (RPDD) from the US ... (RP) with MANF. MANF was previously granted orphan drug ... --> Amarantus BioScience Holdings, Inc. ...
(Date:2/4/2016)... 2016 - New FDA action date of ... FDA action date of July 22, 2016   ... 22, 2016   - Lifitegrast has ... indicated for the treatment of signs and symptoms of dry eye ... potential to be the only product approved in the U.S. in the past decade indicated ...
(Date:2/4/2016)... ... February 04, 2016 , ... ... University’s Digital Forensics Club, takes place February 5-6 at the University’s student ... speakers and activities such as workshops and competitions for ample networking, learning ...
(Date:2/4/2016)... VANCOUVER, British Columbia and MENLO PARK, ... Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical ... therapies, today announced that it will present at the ... on Monday, February 8, 2016 at 10:00 a.m. EST in ... Jeffrey Bacha , DelMar,s president and CEO, will provide an ...
Breaking Biology Technology: